Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Protective immunity against SARS-CoV-2 infection after COVID-19 vaccination may differ by variant. We enrolled vaccinated ( n = 39) and unvaccinated ( n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. For example, among individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all tested variants, including BA.2.
Article activity feed
-
-
SciScore for 10.1101/2022.03.02.22271731: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Study recruitment: This study was approved by the Mass General Brigham institutional review board under protocol 2021P000812.
Consent: Informed consent was obtained from all participants prior to initiating study procedures.
Field Sample Permit: Specimens were transported to the laboratory within four hours of collection.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources ELISA assays were performed using the Elecsys Anti-SARS-CoV-2 ELISA assays for Spike and Nucleocapsid antibodies as per manufacturer instructions (presumed wild type). Anti-SARS-CoV-2suggested: NoneResults from Od…
SciScore for 10.1101/2022.03.02.22271731: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Study recruitment: This study was approved by the Mass General Brigham institutional review board under protocol 2021P000812.
Consent: Informed consent was obtained from all participants prior to initiating study procedures.
Field Sample Permit: Specimens were transported to the laboratory within four hours of collection.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources ELISA assays were performed using the Elecsys Anti-SARS-CoV-2 ELISA assays for Spike and Nucleocapsid antibodies as per manufacturer instructions (presumed wild type). Anti-SARS-CoV-2suggested: NoneResults from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
